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Saliva of blood-sucking arthropods contains a complex mixture of anti-haemostatic, anti-inﬂammatory
and immune-modulator compounds. Among anti-haemostatic factors, there are anticoagulants, vaso-
dilators and platelet aggregation inhibitors. Previous analyses of the sialotranscriptome of Aedes aegypti
showed the potential presence of a Kazal-type serine protease inhibitor in the female salivary glands,
carcass and also in the whole male, which inhibitor we named AaTI (A. aegypti thrombin inhibitor).
Recently, we expressed and characterized rAaTI as a trypsin inhibitor, and its anticoagulant activity [1]. In
this work we characterized the thrombin inhibition mechanism of rAaTI. Recombinant AaTI was able to
prolong prothrombin time, activated partial thromboplastin time and thrombin time. In contrast, AaTID
(rAaTI truncated form) and C-terminal AaTI acidic tail prolong only thrombin time. In the competition
assay, rAaTI, AaTID or C-terminal AaTI acidic tailethrombin interactions seem to be affected by heparin
but not by hirudin, suggesting that rAaTI binds to thrombin exosite 2. Finally, the thrombin inhibition
assay of rAaTI showed an uncompetitive inhibition mechanism. In conclusion, rAaTI can probably inhibit
thrombin by interacting with thrombin exosite 2, and the interaction is not mediated by the AaTI
C-terminal region, since the truncated AaTID form also prolongs thrombin time.
 2010 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Animals belonging to at least fourteen arthropod families
which contain over 400 different genera and more than 15,000
species including Aedes aegypti, evolved independently to feed on
vertebrate blood. To achieve fast blood feeding, adult female
mosquitoes inject sophisticated cocktails of salivary pharmacologic
reagents that affect blood clotting, platelet aggregation and
vascular dilation [2e5].
A. aegypti is the principal vector of dengue and yellow fever
viruses worldwide, mainly because of its adaptability to urban life
and its high susceptibility to dengue virus. Besides, it has a quite
imperceptible bite, and can bite several people in order to acquire
just one blood meal [6].astin time; PT, prothrombin
nhibitor; rAaTIΔ, truncated
bin time.
.
under the Elsevier OA license.Recently, the A. aegypti genome was sequenced, facilitating
further gene discovery. Ribeiro and collaborators analyzed a set of
3776 Salivary Gland cDNA sequences (total of 4232 sequences
when considering a previous set of 456 clones) and identiﬁed 573
new transcripts, from which 136 originate putative secretory
proteins most of them without known function. Among those
sequences, Kazal-type putative protease inhibitors were found
including the sequence gij94468720, which was expressed in the
salivary glands and carcass of female mosquitoes, and also in the
whole male [7].
In invertebrates, a huge number of serine protease inhibitors
have been described, each one showing a different inhibitory
activity, such as tryptase inhibitor, LDTI (Leech derived tryptase
inhibitor) [8], subtilisin inhibitor, infestin 1R [9], and elastase
inhibitor, CmPI-II [10]. Besides, the Kazal-type domain showed
another biological function that was described as the vasoactive
peptide vasotab [11]. Some Kazal-type serine protease inhibitors
identiﬁed in blood-sucking animals are powerful inhibitors of
thrombin and other blood coagulation factor, acting to prevent
clotting during host blood sucking and digestion. The ﬁrst
description of a Kazal-type inhibitor with anticoagulant activity
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nius prolixus [12], followed by dipetalogastin from the insect
Dipetalogaster maximus [13]. Moreover, our group contributed in
describing the thrombin inhibitor infestin 1e2 [14] and a speciﬁc
factor XIIa inhibitor, infestin 4 [15] from the kissing bug Triatoma
infestans midgut, both belonging to the Kazal family.
Thrombin is a serine protease, being a key enzyme of the blood
coagulation cascade and also an important platelet aggregation
activator. This enzyme is peculiar because it has two important
regulatory regions besides the active site, exosites 1 and 2, which
are binding sites for ﬁbrinogen and heparin, respectively [16e18].
Thrombin inhibition can occur through interaction with the
enzyme active site or with its exosites. Rhodniin, ornithodorin and
boophilin inhibition mechanism is similar to hirudin, inhibiting
thrombin by interacting with exosite 1 and active site [19e21]
bothrojaracin binds to exosite 1 and exosite 2 [22], triabin binds
only to the thrombin exosite 1 [23] and haemadin inhibits
thrombin by interacting with the exosite 2 and the active site [24].
Previously, we expressed, puriﬁed and characterized a putative
Kazal-type serine protease inhibitor that is present in different
tissues of A. aegypti, which was named A. aegypti Trypsin Inhibitor
(AaTI). In addition, we showed an anticoagulant activity of this
inhibitor [1]. In the present work, our aimwas the characterization
of the AaTI inhibition mechanism for thrombin.
2. Materials and methods
2.1. Cloning and expression of a truncated form of Kazal-type
inhibitor from A. aegypti (AaTIΔ)
Cloning and expression of rAaTID (rAaTI form without the
C-terminal amino acid sequence, truncated after N-52) was per-
formed as previously described [1]. Brieﬂy, based on AaTI sequence
(GenBank accession number DQ440176), two gene-speciﬁc primers
were designed to amplify AaTID gene fragment by PCR: AaTID
forward 50 e AGCTCTCGAGAAAAGAGAGAGAGGAGTTTGTGC e 30
and AaTIΔ reverse 50 e TTTTCCTTTTGCGGCCGCTCAGTTGTCACAT
GCTTG e 30. AaTIΔ DNA fragment was ampliﬁed using a plasmid
construction containing AaTI DNA fragment. The PCR-ampliﬁed
product was cloned into pPIC9 vector (Invitrogen, Carlsbad, CA,
USA) and the sequence was conﬁrmed by DNA sequencing using
“DYEnamic ET* Terminator Cycle Sequencing” kit (GE Healthcare,
Chalfont St. Giles, UK). Transformed Picha pastoris GS 115 strain
cells were induced with 0.5% methanol every 24 h in BMMY
medium. After 120 h, yeast cell cultures were harvested and the
supernatant (containing secreted rAaTIΔ) was stored at 20 C.
2.2. Synthesis of C-terminal peptide of AaTI
The C-terminal acidic peptide of AaTI (Ace DNLTDNVNDFIPQEYe
NH2) was synthesized using a solid-phase strategy [25], and it was
puriﬁed by preparative reverse phase high performance liquid chro-
matography on a Vydac C18 column. The puriﬁed peptide was charac-
terized by mass spectrometry (LC/ESI-MS) and amino acid analysis.
2.3. Recombinant AaTID puriﬁcation
Recombinant protein was puriﬁed from cell culture supernatant
by afﬁnity chromatography on a trypsineSepharose column. Frac-
tions were eluted with a 0.5 M KCl/0.01 M HCl solution pH 2.0. The
fractions containing inhibitoryactivity towards trypsinwerepooled,
lyophilized and analyzed by SDS-PAGE on 15% polyacrilamide gels
[26]. The active material from the trypsineSepharose column was
applied onto a Superdex 75 column, a gel ﬁltration chromatography,
and the isocratic elution was made in 50 mM Tris/HCl buffer with0.15 M NaCl pH 8.0. To determine the N-terminal amino acid
sequence, the rAaTI puriﬁed by afﬁnity chromatographywas loaded
onto a reverse phase chromatography column (C8 Sephasil Peptide)
connected to theÄKTAPuriﬁer System. Proteinswere elutedwith an
acetonitrile linear gradient (0e90%) in 0.1% triﬂuoroacetic acid.
Puriﬁed rAaTI was submitted to automated Edman degradation for
N-terminal sequencing. Protein concentration was determined by
the Bradford method [27].
2.4. rAaTID inhibitory characterization
Serine protease inhibition tests were carried out in 100 mM
TriseHCl buffer pH 8.0 containing 150 mM NaCl and 0.1% Triton X-
100. Trypsin, plasmin, or thrombin was separately pre-incubated
with different concentrations of rAaTID for 10 min at 37 C. Then,
the enzyme residual activity was tested by addition of chromogenic
substrate (100 mM). Tosyl-Gly-Pro-Arg-pNa (Sigma), S2251 (HD-
Val-Leu-Lys-pNa e Chromogenix), S2238 (HD-Phe-Pip-Arg-pNa e
Chromogenix), respectively, were used as chromogenic substrates.
The reaction mixture was incubated at 37 C for 10 min and the
absorbance at 405 nm was determined using a Synergy HT
microplate reader (BioTek).
2.5. Thrombin inhibition assay using rAaTI
To determine inhibitory activity against thrombin, six different
concentrations of S2238 e HD-Phe-Pip-Arg-pNa (50, 80, 100, 150,
200 and 500 mM) in 100 mM TriseHCl buffer pH 8.0 containing
150 mM NaCl and 0.1% Triton X-100 were used. For each substrate
concentration, rAaTI was used in increasing concentrations (0, 5.2,
13.0, 20.8, 26.0, 52.0, 130.0 and 180.0 nM) and 0.5 U of thrombin in
a total volume of 100 mL. The reactionwas started by the addition of
thrombin. The absorbance at 405 nmwas measured during 10 min
at 37 C. The amount of p-nitroaniline was calculated using a molar
extinction coefﬁcient of 9960. The enzyme activity was calculated
as mmol of p-nitroaniline/min. Ki was calculated using the Cor-
nisheBowden plot ([S]/V  [I]) [28,29].
2.6. Thrombin time
Thrombin time (TT) was measured by pre-incubating 70 mL of
bovine ﬁbrinogen (3.4 mg/mL) and 70 mL of rAaTI (1.3 mM), which
was previously expressed, AaTI synthetic peptide (722 nM) or
rAaTID (880 nM) for 1 min at 37 C. The reaction was activated by
addition of 70 mL of bovine thrombin (5 U/mL), and the clotting time
was measured using the coagulometer.
2.7. Competition assay for thrombin exosite I
Thrombin (106 pM) was pre-incubated with rAaTI (1.04 mM) in
100 mM TriseHCl buffer pH 8.0 containing 150 mM NaCl and 0.1%
Triton X-100 for 10 min at 37 C. After incubation, different
concentrations of hirudin were added to the thrombin and rAaTI
mix, and the residual activity was measured using the ﬂuorogenic
substrate Benzoyl-Phe-Val-Arg-AMC (80 mM). The ﬂuorescence was
measured at lem ¼ 460 nm and lex ¼ 380 nm (emission and exci-
tationwavelengths, respectively) in a Synergy HTmicroplate reader
(BioTek). As a control, the same assay was performed in the absence
of rAaTI.
To verify if hirudin interferes in thrombin inhibition by rAaTI, the
enzyme (106 pM) was pre-incubated with hirudin (106 pM) for
10 min at 37 C. Then, different concentrations of rAaTI were added
and incubated for 10 min at 37 C. The reactionwas monitored after
addition of ﬂuorogenic substrate Benzoyl-Phe-Val-Arg-AMC
(80mM).Asa control, the sameassaywasperformedwithouthirudin.
Fig. 2. Coagulation assays. (A) Prothrombin Time (PT). rAaTI (325 nM) was used in prothrombin time. (B) Activated Partial Thromboplastin Time (APTT). The assay was performed
using 325 nM rAaTI. (C) Thrombin Time (TT) using rAaTI (433 nM). (D) Thrombin Time using rAaTID (346 nM). (E) Thrombin Time using peptide (722 nM). Results are the mean of
triplicate points  standard deviation.
Fig. 1. Alignment of amino acid sequences of AaTI, AaTIΔ and C-terminal peptide with other thrombin inhibitor of Kazal-type family. Rhod_D1, rhodniin ﬁrst domain [12]; inf_D1,
infestin ﬁrst domain [14]; LDTI-5T, leech derived tryptase inhibitor mutant 5T e thrombin inhibitor [35]. All identical amino acid residues are shaded in light grey. AaTI amino acid
residue that is identical to one or more of other sequence is shaded in dark grey.
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To verify whether heparin and antithrombin III binding to
thrombin interfered in thrombin inhibition by rAaTI, thrombin
(106 pM) was pre-incubated with heparin (1 ng/mL) and anti-
thrombin III (167 pM) for 10 min at 37 C. Afterwards, different
concentrations of rAaTI were added to the mix and incubated for
10 min at 37 C. The enzyme residual activity was measured
using the ﬂuorogenic substrate Benzoyl-Phe-Val-Arg-AMC
(80 mM). A thrombin inhibition curve was also constructed using
thrombin in low concentration (2.12 pM) and rAaTI concentra-
tions between 52 nM and 1300 nM. The residual activity towards
the ﬂuorogenic substrate was monitored using the ﬂuorogenic
substrate and the reaction was monitored using the excitation
wavelength of 380 nm and emission measured at 460 nm for
20 min at 37 C.
2.9. Inhibition assay for thrombins
Alpha-thrombin (0.025 U) or gamma-thrombin (1 mg) was pre-
incubated with rAaTI (0.38e1.56 mM) in 100 mM TriseHCl buffer
pH 8.0 containing 150 mM NaCl and 0.1% Triton X-100 for 15 min
at 37 C. After incubation at the same conditions (20 min), the
residual activity was measured using the ﬂuorogenic substrate
Benzoyl-Phe-Val-Arg-AMC (200 mM). The ﬂuorescence was
measured at lem ¼ 460 nm and lex ¼ 380 nm (emission and
excitation wavelengths, respectively) in a Synergy HT microplate
reader (BioTek). As a control, the same assay was performed in the
absence of rAaTI.Fig. 3. Exosites competition assays. Exosite 1 competition assay. (A) Hirudin inhibitory activ
(B) rAaTI inhibitory activity against thrombin without hirudin (- -) and in the presence of
hirudin concentration able to inhibit 50% of thrombin to verify if its binding in exosite I coul
the presence and in the absence of antithrombin III and heparin. First, it was veriﬁed if r
inhibited by antithrombin (167 pM) in the presence of heparin (1 ng/L) (-B-). In order to si
the inhibitory assay (-:-).3. Results and discussion
In this work we described the cloning, expression, puriﬁcation
and characterization of the AaTID (AaTI without C-terminal acidic
peptide). rAaTI was previously expressed, puriﬁed and character-
ized, and it displayed anticoagulant activity [1].Multiple alignments
of AaTI, AaTID, C-terminal acidic peptide with other Kazal-type
thrombin inhibitors revealed high similarity in the molecule core
and also in the C-terminal end (Fig. 1). Thrombin, a key enzyme of
blood coagulation cascade, possesses three functional domains: the
active site, the exosite 1 and the exosite 2. The thrombin inhibitors
have different mechanisms of inhibition. While hirudin [30],
rhodniin [31], ornithodorin [21], savignin [32], dipetalogastin [13],
boophilin [20] interact with both active site and exosite 1; triabin
[33] binds only to exosite 1; haemadin [24] binds to exosite 2 and
active site, and bothrojaracin [22] binds to both exosites but it does
not bind to the active site.
In order to conﬁrm the AaTI inhibitorymechanism for thrombin,
we cloned the truncated form of A. aegypti Kazal-type serine
protease inhibitor gene fragment (AaTID) which encodes a protein
of 5.8 kDa and theoretical pI 7.8. rAaTID cloning and expressionwas
performedas previouslydescribed for the full lengthprotein [1]. The
fragment sequencewas veriﬁed byDNA sequencing, and rAaTIDwas
expressed in P. pastoriswith an yield of 1.1 mg/L of culture medium.
rAaTIΔ, expressed in the P. pastoris system, was puriﬁed from
the culture supernatant using trypsineSepharose afﬁnity chro-
matography. The fractions containing inhibitory activity against
trypsin were pooled, and submitted to SDS-PAGE. The eluted
fractions of afﬁnity chromatography were applied in a gel ﬁltrationity against thrombin in the presence of rAaTI (1.04 mM) (-B-) and without rAaTI (- -).
hirudin (106 pM) (-B-). In rAaTI inhibitory activity against thrombin it was used an
d interfere in rAaTI activity. Exosite 2 competition assay. (C) rAaTI inhibitory activity in
AaTI inhibitory activity against thrombin 106 pM (- -), then thrombin (106 pM) was
mulate free thrombin (not inhibited by antithrombin), thrombin (2.12 pM) was used in
Fig. 5. rAaTI inhibition curve for alpha- and gamma-thrombin. Alpha-thrombin (0.025
U) or gamma-thrombin (1 mg) was pre-incubated with rAaTI different concentrations
(0.38e1.56 mM) in 0.1 M tris buffer pH 8.0 for 15 min at 37 C. The enzymatic activity
was measured by addition of ﬂuorogenic substrate, Benzoyl-Phe-Val-Arg-AMC
(0.2 mM) and incubation for 20 min at 37 C.
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inhibited trypsin and plasmin activities. Previous results showed
that rAaTI weakly inhibited thrombin amidolytic activity while
rAaTIΔ did not, suggesting that C-terminal charged peptide in
rAaTIΔ may have an important role in thrombin inhibition, which
negatively affects binding strength, if the AaTI has a bidentate
interaction with the enzyme.
rAaTI showed similar activities to anticoagulants, containing
a C-terminal charged peptide, the same as for other thrombin
inhibitors, like hirudin [30], dipetalogastin [13] and rhodniin [31],
suggesting that C-terminal region might be important to the rAaTI
activity. rAaTI was tested in coagulation assays, and prolonged
APTT, PT and TT (Fig. 2AeC) [1], which suggested that it acted as
a thrombin inhibitor. C-terminal peptide and rAaTIΔ also affected
the thrombin time showing that both parts of AaTI may have an
important role in thrombin inhibition (Fig. 2DeE). Thrombin Time
observed behavior can result from steric hindering of substrate
binding. rAaTID could also prolong thrombin time similarly to
rAaTI, suggesting that it may bind to another site than the thrombin
active site, which would allow the synthetic substrate hydrolysis
but impairing ﬁbrinogen cleavage. rAaTI and its truncated form
were also tested in a thrombin-induced platelet aggregation assay,
but none of them affected this process. This fact could be explained
by rAaTI not binding directly to the exosite 1. This result was
conﬁrmed by exosite 1 competition assay, which showed that
neither hirudin could affect the rAaTI inhibition nor rAaTI affected
the hirudin inhibition of thrombin (Fig. 3A and B). In the exosite 2
competition assay, when thrombin (106 pM) was previously
inhibited by antithrombin III in the presence of heparin, resulting in
w4% residual activity of thrombin (w2.0 pM) (data not shown), the
inhibitory activity of rAaTI seemed to be higher when compared to
the rAaTI inhibitory activity against thrombin 106 pM, showing that
it weakly inhibits thrombin. In order to simulate the free thrombin
(not inhibited by antithrombin III), thrombin 2.12 pM was used
(Fig. 3C), and we veriﬁed that the rAaTI inhibitory activity was
similar in both cases. This result suggested that rAaTI may bind to
the same region where antithrombin III or heparin binds on the
thrombin surface. Classical inhibition experiments showed an
uncompetitive inhibition mechanism for rAaTI and thrombin
(Fig. 4). This result suggests that rAaTI interacts with the enzy-
meesubstrate complex, decreasing both Km and Vapp. Ki was
calculated using the CornisheBowden plot ([S]/v  [I]), and its
value was 320 nM.
Inanattempt toverify the importanceof thrombinexosite1 in the
rAaTI inhibitory activity, it was performed an inhibition assay usingFig. 4. rAaTI inhibition curve for thrombin. The experiment was composed by six
curves using different concentrations of S2238 (50, 80, 100, 150, 200 and 500 mM). For
each curve, rAaTI was used in increasing concentrations (0, 5.2, 13.0, 20.8, 26.0, 52.0,
130.0 and 180.0 nM) and thrombin 2.5 U/mL. Reactions were started by addition of
thrombin to substrate-inhibitor mixture and Ki was calculated using the Cor-
nisheBowden plot ([S]/V  [I]).gamma-thrombin, an enzyme which has only the active site and
exosite 2 [34]. Our results showed that the absence of exosite 1 did
not interfere in the gamma-thrombin by rAaTI suggesting that the
inhibitor does not require this site to inhibit alpha-thrombin (Fig. 5).
In addition, the AaTI transcript is found in female salivary gland
and gut, suggesting also a possible role as a gut anticoagulant
molecule.
On the basis of our results, we can conclude that AaTI is a serine
protease inhibitor with thrombin anticoagulant activity, and it
weakly interacts with the enzyme at a region other than the active
site, probably to the exosite 2of thrombinbutnot to theexosite 1 and
may be stabilized by the C-terminal tail by electrostatic interactions.Acknowledgments
We thank Dr. Izaura Y. Hirata of Departamento de Biofísica
(UNIFESP-Brazil) for performing amino acid sequencing, Dr. Mar-
celo L. Santoro of Laboratório de Fisiopatologia (Instituto Butantan-
Brazil) for performing platelet aggregation test and and Dr.
Mariângela Dametto from Albert Einstein College of Medicine, NY,
for reading and helping in the English correction. This work was
supported by grants from Fundação de Amparo à Pesquisa do
Estado de São Paulo (05/03514-9) and Conselho Nacional de
Desenvolvimento Cientíﬁco e Tecnológico (470070/2004-8;
575829/2008-7). R.M.OWatanabe was supported with a fellowship
by FAPESP (07/56614-6).References
[1] R.M. Watanabe, T.S. Soares, K. Morais-Zani, A.M. Tanaka-Azevedo, C. Maciel,
M.L. Capurro, R.J. Torquato, A.S. Tanaka, A novel trypsin Kazal-type inhibitor
from Aedes aegypti with thrombin coagulant inhibitory activity, Biochimie 92
(2010) 933e939.
[2] K.R. Stark, A.A. James, A factor Xa-directed anticoagulant from the salivary
glands of the yellow fever mosquito Aedes aegypti, Exp. Parasitol. 81 (1995)
321e331.
[3] S. Yoshida, T. Sudo, M. Niimi, L. Tao, B. Sun, J. Kambayashi, H. Watanabe, E. Luo,
H. Matsuoka, Inhibition of collagen-induced platelet aggregation by anophe-
line antiplatelet protein, a saliva protein from a malaria vector mosquito,
Blood 111 (2008) 2007e2014.
[4] E. Calvo, F. Tokumasu, O. Marinotti, J.L. Villeval, J.M. Ribeiro, I.M. Francischetti,
Aegyptin, a novel mosquito salivary gland protein, speciﬁcally binds to
collagen and prevents its interaction with platelet glycoprotein VI, integrin
alpha2beta1, and von Willebrand factor, J. Biol. Chem. 282 (2007)
26928e26938.
[5] J.M. Ribeiro, R.H. Nussenzveig, G. Tortorella, Salivary vasodilators of Aedes
triseriatus and Anopheles gambiae (Diptera: Culicidae), J. Med. Entomol. 31
(1994) 747e753.
[6] D.J. Gubler, The global emergence/resurgence of arboviral diseases as public
health problems, Arch. Med. Res. 33 (2002) 330e342.
R.M.O. Watanabe et al. / Biochimie 93 (2011) 618e623 623[7] J.M. Ribeiro, B. Arca, F. Lombardo, E. Calvo, V.M. Phan, P.K. Chandra, S.K. Wikel,
An annotated catalogue of salivary gland transcripts in the adult female
mosquito, Aedes aegypti, BMC Genomics 8 (2007) 6.
[8] C.P. Sommerhoff, C. Sollner, R. Mentele, G.P. Piechottka, E.A. Auerswald,
H. Fritz, A Kazal-type inhibitor of human mast cell tryptase: isolation from the
medical leech Hirudo medicinalis, characterization, and sequence analysis, Biol.
Chem. Hoppe Seyler 375 (1994) 685e694.
[9] D.V. Lovato, I.T. Nicolau de Campos, R. Amino, A.S. Tanaka, The full-length
cDNA of anticoagulant protein infestin revealed a novel releasable Kazal
domain, a neutrophil elastase inhibitor lacking anticoagulant activity, Bio-
chimie 88 (2006) 673e681.
[10] Y. Gonzalez, T. Pons, J. Gil, V. Besada, M. Alonso-del-Rivero, A.S. Tanaka,
M.S. Araujo, M.A. Chavez, Characterization and comparative 3D modeling of
CmPI-II, a novel ‘non-classical’ Kazal-type inhibitor from the marine snail
Cenchritis muricatus (Mollusca), Biol. Chem. 388 (2007) 1183e1194.
[11] P. Takac, M.A. Nunn, J. Meszaros, O. Pechanova, N. Vrbjar, P. Vlasakova,
M. Kozanek, M. Kazimirova, G. Hart, P.A. Nuttall, M. Labuda, Vasotab, a vaso-
active peptide from horse ﬂy Hybomitra bimaculata (Diptera, Tabanidae)
salivary glands, J. Exp. Biol. 209 (2006) 343e352.
[12] T. Friedrich, B. Kroger, S. Bialojan, H.G. Lemaire, H.W. Hoffken,
P. Reuschenbach, M. Otte, J. Dodt, A Kazal-type inhibitor with thrombin
speciﬁcity from Rhodnius prolixus, J. Biol. Chem. 268 (1993) 16216e16222.
[13] K. Mende, O. Petoukhova, V. Koulitchkova, G.A. Schaub, U. Lange, R. Kaufmann,
G. Nowak, Dipetalogastin, a potent thrombin inhibitor from the blood-sucking
insect. Dipetalogaster maximus cDNA cloning, expression and characterization,
Eur. J. Biochem. 266 (1999) 583e590.
[14] I.T. Campos, R. Amino, C.A. Sampaio, E.A. Auerswald, T. Friedrich, H.G. Lemaire,
S. Schenkman, A.S. Tanaka, Infestin, a thrombin inhibitor presents in Triatoma
infestans midgut, a Chagas’ disease vector: gene cloning, expression and
characterization of the inhibitor, Insect Biochem. Mol. Biol. 32 (2002)
991e997.
[15] I.T. Campos, A.M. Tanaka-Azevedo, A.S. Tanaka, Identiﬁcation and character-
ization of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma
infestans (Hemiptera: Reduviidae), FEBS Lett. 577 (2004a) 512e516.
[16] M. Kaminski, J. McDonagh, Inhibited thrombins. Interactions with ﬁbrinogen
and ﬁbrin, Biochem. J. 242 (1987) 881e887.
[17] W. Bode, I. Mayr, U. Baumann, R. Huber, S.R. Stone, J. Hofsteenge, The reﬁned
1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-
Arg chloromethylketone and signiﬁcance of the Tyr-Pro-Pro-Trp insertion
segment, EMBO J. 8 (1989) 3467e3475.
[18] F.C. Church, C.W. Pratt, C.M. Noyes, T. Kalayanamit, G.B. Sherrill, R.B. Tobin,
J.B. Meade, Structural and functional properties of human alpha-thrombin,
phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identiﬁca-
tion of lysyl residues in alpha-thrombin that are critical for heparin and ﬁbrin
(ogen) interactions, J. Biol. Chem. 264 (1989) 18419e18425.
[19] R.N. Araujo, I.T. Campos, A.S. Tanaka, A. Santos, N.F. Gontijo, M.J. Lehane,
M.H. Pereira, Brasiliensin: a novel intestinal thrombin inhibitor from Triatoma
brasiliensis (Hemiptera: Reduviidae) with an important role in blood intake,
Int. J. Parasitol. 37 (2007) 1351e1358.
[20] S. Macedo-Ribeiro, C. Almeida, B.M. Calisto, T. Friedrich, R. Mentele,
J. Sturzebecher, P. Fuentes-Prior, P.J. Pereira, Isolation, cloning and structuralcharacterisation of boophilin, a multifunctional Kunitz-type proteinase
inhibitor from the cattle tick, PLoS ONE 3 (2008) e1624.
[21] A. van de Locht, M.T. Stubbs, W. Bode, T. Friedrich, C. Bollschweiler,
W. Hoffken, R. Huber, The ornithodorin-thrombin crystal structure, a key to
the TAP enigma? EMBO J. 15 (1996) 6011e6017.
[22] V. Arocas, R.B. Zingali, M.C. Guillin, C. Bon, M. Jandrot-Perrus, Bothrojaracin:
a potent two-site-directed thrombin inhibitor, Biochemistry 35 (1996)
9083e9089.
[23] P. Fuentes-Prior, C. Noeske-Jungblut, P. Donner, W.D. Schleuning, R. Huber,
W. Bode, Structure of the thrombin complex with triabin, a lipocalin-like
exosite-binding inhibitor derived from a triatomine bug, Proc. Natl. Acad. Sci.
U.S.A. 94 (1997) 11845e11850.
[24] J.L. Richardson, B. Kroger, W. Hoeffken, J.E. Sadler, P. Pereira, R. Huber,
W. Bode, P. Fuentes-Prior, Crystal structure of the human alpha-thrombin-
haemadin complex: an exosite II-binding inhibitor, EMBO J. 19 (2000)
5650e5660.
[25] L. Juliano, M.A. Juliano, A. De Miranda, S. Tsuboi, Y. Okada, Amino acids and
peptides. XVI. Synthesis of NG-tosylarginyl peptide derivativeseobservation
of lactam formation of arginyl residue, Chem. Pharm. Bull. (Tokyo) 35 (1987)
2550e2553.
[26] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head
of bacteriophage T4, Nature 227 (1970) 680e685.
[27] M.M. Bradford, A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding, Anal.
Biochem. 72 (1976) 248e254.
[28] M. Dixon, The determination of enzyme inhibitor constants, Biochem. J. 55
(1953) 170e171.
[29] S. Visetnan, S. Donpudsa, P. Supungul, A. Tassanakajon, V. Rimphanitchayakit,
Kazal-type serine proteinase inhibitors from the black tiger shrimp Penaeus
monodon and the inhibitory activities of SPIPm4 and 5, Fish Shellﬁsh Immu-
nol. 27 (2009) 266e274.
[30] M.G. Grutter, J.P. Priestle, J. Rahuel, H. Grossenbacher, W. Bode, J. Hofsteenge,
S.R. Stone, Crystal structure of the thrombin-hirudin complex: a novel mode
of serine protease inhibition, EMBO J. 9 (1990) 2361e2365.
[31] A. van de Locht, D. Lamba, M. Bauer, R. Huber, T. Friedrich, B. Kroger,
W. Hoffken, W. Bode, Two heads are better than one: crystal structure of the
insect derived double domain Kazal inhibitor rhodniin in complex with
thrombin, EMBO J. 14 (1995) 5149e5157.
[32] B.J. Mans, A.I. Louw, A.W. Neitz, Amino acid sequence and structure modeling
of savignin, a thrombin inhibitor from the tick, Ornithodoros savignyi, Insect
Biochem. Mol. Biol. 32 (2002) 821e828.
[33] C. Noeske-Jungblut, B. Haendler, P. Donner, A. Alagon, L. Possani,
W.D. Schleuning, Triabin, a highly potent exosite inhibitor of thrombin, J. Biol.
Chem. 270 (1995) 28629e28634.
[34] J.W. Fenton 2nd, T.A. Olson, M.P. Zabinski, G.D. Wilner, Anion-binding exosite
of human alpha-thrombin and ﬁbrin(ogen) recognition, Biochemistry 27
(1988) 7106e7112.
[35] A.S. Tanaka, M.M. Silva, R.J. Torquato, M.A. Noguti, C.A. Sampaio, H. Fritz,
E.A. Auerswald, Functional phage display of leech-derived tryptase inhibitor
(LDTI): construction of a library and selection of thrombin inhibitors, FEBS
Lett. 458 (1999) 11e16.
